For life, creating the possible

Committed to providing more optimized products and treatment programs for global doctors and patients

Weike Medical

Wuhan Weike Medical Technology Co., Ltd. was established in July 2018,Focus on major clinical needs in the cardiovascular field, especially in the field of heart failure and structural heart disease.It is committed to creating an innovative medical device platform for cardiovascular full-cycle solutions through research and development, technical services, production and sales, and providing more optimized products and treatment plans for global doctors and patients.

 

The company is headquartered in Wuhan East Lake High-tech Zone, and in Suzhou, Beijing, Shanghai and other places of the layout of the industrial chain upstream and downstream. The founder and scientific research team of the company are composed of structural heart disease intervention experts, cardiac surgery experts, metal materials experts, weaving device research and development experts, and medical device registration experts, forming a strong combination of medical research and enterprise.

 

The products cover many fields, including atrial shunt related to heart failure prevention, patent foramen ovale occluder related to cardiac stroke prevention, transcatheter aortic valve replacement system related to valve disease treatment, and related surgical accessories consumables. More than 60 patents have been applied for, including more than 50 invention patents, 10 utility model patents, and 3 PCT patents. Related products have complete independent intellectual property rights. Atrial shunts were approved by the NMPA "Special Review Procedure for Innovative Medical Devices" and FDA "Breakthrough Medical Device Designation".

 

Innovation is rooted in the heart. In the future, Weike Medical will continue to deepen the field of heart failure and structural heart disease, guided by the needs of global doctors and patients, and contribute more innovative forces to the cause of human health.

Weike Medical

Milestone

November 2023

D-shant® Atrial Shunt receives FDA Breakthrough Medical Device Designation

August 2023

Vickor Medical (Shanghai) branch was completed and put into operation

June 2023

Astross™ Heart Occluder delivery system approved for NMPA registration

May 2023

First clinical application of DOCS VALVE® transcatheter aortic valve replacement system

March 2023

Won the B+ round of financing led by Hubei Financial Holding

March 2023

Awarded as Hubei Province specialized special new enterprise

December 2022

Vickor Medical (Beijing) branch was completed and put into operation

September 2022

Vickor Medical (Suzhou) subsidiary was completed and put into operation

June 2022

D-shant® atrial shunt was selected into the National Innovative Medical Device Green Channel

May 2022

Awarded as listed gold seed enterprise in Hubei Province

July 2021

The new plant was completed and put into use

November 2021

Received Series B funding led by Sequoia China

March 2021

National multi-center clinical trial of D-shant® atrial shunt initiated

December 2020

Awarded high-tech enterprise

November 2020

Won A round of financing led by Mountain Blue Capital

September 2020

National multi-center clinical trial of D-shufo™ patent foramen ovale occluder initiated

July 2019

D-shant® atrial shunt developed successfully

February 2019

Received angel round funding from Proxima Ventures

July 2018

Vickor Medical was established

Enterprise culture

Trust

Respect for trust, openness and inclusiveness

Collaboration

Collaborative cooperation, mutual benefit and win-win

Innovation

From demand, create value

Development

Shared development, leading the future

Social responsibility

Weike Medical adheres to the spirit of giving back innovative results to the society, and adheres to the combination of scientific and technological innovation and clinical needs,

We are committed to providing safer and more effective treatment for patients.